Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases
This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.